Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ANIK
ANIK logo

ANIK Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Anika Therapeutics Inc (ANIK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
15.870
1 Day change
-1.00%
52 Week Range
16.490
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ANIK is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 available. The stock has some short-term technical strength, but the lack of recent news, weak conviction from proprietary signals, neutral insider/hedge fund activity, and no clear financial snapshot make it better suited to a wait-and-see approach rather than an immediate long-term purchase. Since the user is impatient and unwilling to wait for an optimal entry point, my direct view is still not to buy now.

Technical Analysis

The trend is mildly bullish. MACD histogram is positive and expanding, which supports upside momentum. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, showing the stock is above its longer-term trend. RSI_6 at 67.949 is near overbought but still not an outright sell signal. Price at 15.34 is just below resistance at R1 15.353, so upside may be capped near-term unless it breaks through 15.353 and then 15.763. Support sits at 14.688, then 14.023. The pattern-based outlook is weak in the very near term, with a 60% chance of -4.63% next day, which reduces confidence for immediate entry.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish based on open interest, with a low put-call ratio of 0.22, meaning calls heavily outweigh puts. However, option volume is flat at 0, so the signal reflects positioning more than active trading conviction. Implied volatility is elevated at 71.12 versus historical volatility of 27.59, suggesting the market expects bigger moves, but today’s lack of volume weakens the case for a strong immediate trade. The options setup is mildly positive but not enough to override the broader lack of catalysts.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
9

Positive Catalysts

  • ["Bullish moving average structure: SMA_5 > SMA_20 > SMA_200", "MACD histogram is positive and expanding", "Low put-call ratio of 0.22 suggests bullish positioning in options", "Price is trading above the pivot level, showing short-term strength"]

Neutral/Negative Catalysts

  • ["No news in the recent week, so no event-driven catalyst", "AI Stock Picker: no signal on given stock today", "SwingMax: no signal on given stock recently", "Hedge funds are neutral with no significant trading trends", "Insiders are neutral with no significant trading trends", "No recent congress trading data available", "Pattern-based forecast suggests weakness in the next day and month", "Price is close to resistance, limiting immediate upside"]

Financial Performance

No usable financial snapshot was provided, so the latest quarter cannot be assessed reliably. The company’s most recent quarter season is therefore unavailable from the data given, and there is no confirmed revenue, earnings, or growth trend to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence of a recent positive revision cycle. Based on the available information, Wall Street sentiment appears mixed to neutral: technicals and options are somewhat constructive, but the absence of news, analyst upgrades, and insider/hedge fund buying limits the bullish case.

Wall Street analysts forecast ANIK stock price to fall
1 Analyst Rating
Wall Street analysts forecast ANIK stock price to fall
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 16.030
sliders
Low
16
Averages
16
High
16
Current: 16.030
sliders
Low
16
Averages
16
High
16
B. Riley
Buy
maintain
$16 -> $18
AI Analysis
2026-02-27
Reason
B. Riley
Price Target
$16 -> $18
AI Analysis
2026-02-27
maintain
Buy
Reason
B. Riley raised the firm's price target on Anika Therapeutics to $18 from $16 and keeps a Buy rating on the shares. Anika Therapeutics reported strong Q4 results, with revenue of $30.6M in line with expectations and adjusted EBITDA of $4.5M well above consensus, driven by commercial channel growth, international OA pain expansion, and improved manufacturing margins, the analyst tells investors in a research note.
Barrington
Michael Petusky
Outperform
maintain
$16 -> $17
2026-02-27
Reason
Barrington
Michael Petusky
Price Target
$16 -> $17
2026-02-27
maintain
Outperform
Reason
Barrington analyst Michael Petusky raised the firm's price target on Anika Therapeutics to $17 from $16 and keeps an Outperform rating on the shares. The company reported a Q4 beat, the analyst tells investors in a research note. The firm says that despite yesterday's 16% rally, Anika remains "meaningfully undervalued."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ANIK
Unlock Now

People Also Watch